(2R)-3-[[9-propan-2-yl-6-[(4-pyridin-2-ylphenyl)methylamino]purin-2-yl]amino]propane-1,2-diol | 1243148-45-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2R)-3-[[9-propan-2-yl-6-[(4-pyridin-2-ylphenyl)methylamino]purin-2-yl]amino]propane-1,2-diol
• CAS: 1243148-45-9
• 化学式: C₂₃H₂₇N₇O₂
• 分子量: 433.513
• InChiKey: BIUDJFOTQAVFMN-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-Boc-L-缬氨酸 、 (2R)-3-[[9-propan-2-yl-6-[(4-pyridin-2-ylphenyl)methylamino]purin-2-yl]amino]propane-1,2-diol 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 12.0h， 以76%的产率得到[(2R)-2-hydroxy-3-[[9-isopropyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propyl] (2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoate
  参考文献：
  名称：

  [EN] METHOD OF TREATMENT OF POLYCYSTIC DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA
  [FR] PROCÉDÉ DE TRAITEMENT DES MALADIES POLYKYSTIQUES ET DE LA LEUCÉMIE LYMPHOCYTAIRE CHRONIQUE

  摘要：

  本发明涉及一种治疗多囊疾病或减少和/或避免囊肿形成的方法，包括至少一步，即向患有囊性疾病的患者施用有效量的式（VII）的2,6,9-三取代嘌呤化合物的方法：其中A代表可选择的（A.1）或（A.2）基团。

  公开号：

  WO2010103473A1

文献信息

• Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors
  作者：Joannah N'gompaza-Diarra、Karima Bettayeb、Nohad Gresh、Laurent Meijer、Nassima Oumata

  DOI：10.1016/j.ejmech.2012.08.033

  日期：2012.10

  A new series of 2,6,9-trisubstituted purines, structurally related to the cyclin-dependent kinase (CDK) inhibitor Roscovitine, has been synthesized. These compounds mainly differ by the substituent on the C-2 position which encompasses a diol group. These compounds were screened for kinase inhibitory activities and antiproliferative effects. They were shown to be potent inhibitors of cyclin-dependent kinases but also, for some of them of casein kinase 1 (CK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). The inhibition of kinases was accompanied by an antiproliferative effect against several tumor cell-lines. The most potent derivatives inhibited SH-SY5Y (neuroblastoma) tumor cell line with an IC50 < 0.5 mu M which means approximately a 30 fold increase compared to Roscovitine. A valine ester was also prepared from the most potent inhibitor to serve as a prodrug. (C) 2012 Elsevier Masson SAS. All rights reserved.